论文部分内容阅读
目的探讨血清人附睾分泌蛋白4、CA125检测及ROMA指数鉴别诊断上皮性卵巢癌的临床应用价值。方法分别采用ELISA法和微粒子化学发光法测定46例上皮性卵巢癌患者(EOC)、49例良性肿瘤患者和50例健康体检者血清HE4、CA125水平,计算出ROMA指数。结果 EOC与健康对照组相比,HE4、CA125及ROMA指数诊断上皮性卵巢癌的AUC分别为0.915、0.818和0.948;EOC与良性肿瘤相比,HE4、CA125及ROMA指数诊断卵巢恶性肿瘤的AUC分别为0.833、0.755和0.870。结论人附睾分泌蛋白4是一种有效的卵巢癌肿瘤标志物,联合CA125检测计算ROMA指数可显著提高卵巢癌的诊断效率。
Objective To investigate the clinical value of serum human epididymal secreted protein 4, CA125 and ROMA index in the differential diagnosis of epithelial ovarian cancer. Methods The serum levels of HE4 and CA125 were measured in 46 patients with epithelial ovarian cancer (EOC), 49 patients with benign tumor and 50 healthy controls by ELISA and microparticle chemiluminescence. ROMA index was calculated. Results Compared with healthy controls, the AUC of HE4, CA125 and ROMA index in diagnosis of epithelial ovarian cancer were 0.915, 0.818 and 0.948, respectively. Compared with benign tumors, the AUCs of HE4, CA125 and ROMA index in diagnosis of ovarian malignant tumors 0.833, 0.755 and 0.870. Conclusions Human epididymal secreting protein 4 is an effective tumor marker of ovarian cancer. Combined with CA125 detection and calculation of ROMA index can significantly improve the diagnostic efficiency of ovarian cancer.